Corcept Therapeutics Stops Enrollment In RELIANT Trial; Says ‘the apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer’
Enrollment stopped in RELIANT trial
Antitumor activity observed in heavily pretreated patients with metastatic pancreatic cancer, including those previously treated with nab-paclitaxel; addition of relacorilant to